Drugs Containing Excipient (Inactive Ingredient) ARACHIS HYPOGAEA

Generic drugs containing ARACHIS HYPOGAEA excipient

Company	Ingredient	NDC	Excipient
A-S Medication Solutions	fluocinolone acetonide	50090-6780	ARACHIS HYPOGAEA

Arachis Hypogaea Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: August 2, 2026

Arachis hypogaea is the botanical source of peanut oil, also called arachis oil or peanut oil. In pharmaceuticals, it is a fixed vegetable oil used mainly as a solvent, vehicle, emollient, and carrier in oral, topical, and selected parenteral formulations. Its commercial position is constrained by peanut-allergy risk, mandatory excipient disclosure in several markets, variable agricultural supply, and competition from soybean, sesame, sunflower, mineral, and medium-chain triglyceride oils.

Arachis hypogaea is not an independently reported pharmaceutical market category. Suppliers generally report revenue within broader pharmaceutical excipients, vegetable oils, specialty lipids, or contract-manufactured formulation ingredients. Its financial trajectory is therefore best assessed through demand in lipid-based formulations, regulatory costs, raw-material pricing, and substitution risk rather than through a standalone market-size forecast.

What is Arachis hypogaea used for in pharmaceutical formulations?

Arachis hypogaea oil is a refined fixed oil derived from peanut seeds. Its principal pharmaceutical functions include:

Function	Formulation role	Commercial relevance
Solvent	Dissolves lipophilic active pharmaceutical ingredients	Relevant in soft capsules, depot injections, and oil-based solutions
Vehicle	Carries an active ingredient in oral, topical, or injectable dosage forms	Supports established products but creates route-specific safety requirements
Emollient	Softens and protects skin	Used in dermatological and cosmetic pharmaceutical products
Lubricant	Reduces friction during processing or administration	Usually replaceable by other oils or excipients
Lipid carrier	Provides an oil phase for drug delivery	Faces competition from MCT oil, soybean oil, and synthetic lipids

Arachis hypogaea oil is most defensible commercially where a formulation has already been developed, validated, and approved around its physicochemical properties. New-product developers have greater flexibility to select alternatives before formulation lock.

The excipient’s performance depends on fatty-acid composition, oxidation profile, water content, peroxide value, acid value, microbial quality, and residual protein control. Pharmaceutical-grade material requires tighter specifications than food-grade peanut oil.

What pharmaceutical products contain Arachis hypogaea oil?

Arachis hypogaea oil appears in established drug formulations, including products using peanut oil as an inactive ingredient or oil vehicle. The most visible example is oral micronized progesterone marketed in the United States as Prometrium, whose labeling identifies peanut oil among the inactive ingredients (DailyMed, n.d.).

Product-specific use depends on the manufacturer, dosage form, jurisdiction, and formulation version. The presence of peanut oil must be confirmed through the relevant product label rather than inferred from the active ingredient.

Oral dosage forms

Peanut oil can dissolve or disperse lipophilic active ingredients in soft gelatin capsules and other lipid-based oral systems. Its use is technically established but commercially exposed to allergy-related prescribing restrictions and patient avoidance.

Topical dosage forms

The oil can function as an emollient or carrier in dermatological products. Topical use may reduce systemic exposure, but it does not eliminate the need for ingredient disclosure or allergen risk assessment.

Parenteral dosage forms

Oil-based injections require strict control of sterility, endotoxins, particulate matter, oxidation, and injection-site tolerability. Peanut oil is therefore less interchangeable in parenteral products than in topical or nonsterile formulations. A change to another oil can require formulation comparability, stability work, process validation, and regulatory notification or approval.

What is the FDA regulatory status of Arachis hypogaea oil?

Arachis hypogaea oil is an established pharmaceutical excipient rather than a new active pharmaceutical ingredient. The FDA Inactive Ingredient Database includes inactive ingredients used in approved drug products, with entries organized by ingredient, route, dosage form, and maximum potency where available (U.S. Food and Drug Administration, n.d.-a).

The database does not create a universal approval for every grade, supplier, route, or concentration. A sponsor must establish that the selected material is suitable for its formulation and manufacturing process.

Key FDA considerations include:

• Identity and compendial quality.
• Route-specific safety.
• Residual peanut protein and allergen controls.
• Oxidative stability.
• Microbiological quality.
• Compatibility with the active ingredient and container-closure system.
• Accurate inactive-ingredient disclosure.

Arachis hypogaea oil is not an active ingredient with its own FDA exclusivity period. Its regulatory value comes from prior use, established quality standards, and formulation know-how.

What is the Orange Book status of Arachis hypogaea oil?

Arachis hypogaea oil does not have an independent Orange Book listing. The FDA Orange Book lists approved drug products, reference listed drugs, patent information, and exclusivity associated with finished products, not standalone excipients (U.S. Food and Drug Administration, n.d.-b).

The practical consequences are:

Issue	Status for Arachis hypogaea oil
Standalone Orange Book listing	None
Active-ingredient exclusivity	None
Excipient-specific patent term	None as a general category
Paragraph IV challenge	Not applicable to the excipient itself
Finished-product patent risk	Possible where a drug patent claims a formulation containing the oil
ANDA relevance	Relevant only as part of a finished drug’s formulation and sameness analysis

A generic applicant may need to address a formulation patent that claims a particular oil, concentration, capsule composition, release profile, or method of use. That is different from challenging rights in Arachis hypogaea oil as a substance.

When does Arachis hypogaea lose exclusivity?

Arachis hypogaea oil has no standalone exclusivity date. The underlying ingredient is a naturally derived excipient with long-established commercial and pharmaceutical use.

Exclusivity can exist at the finished-product level through:

• New chemical entity exclusivity for an active ingredient.
• New clinical investigation exclusivity.
• Orphan-drug exclusivity.
• Pediatric exclusivity.
• Patents covering a formulation, dosage form, manufacturing process, or method of use.

Those rights attach to the approved drug or claimed invention, not to peanut oil generally. A formulation patent may expire while supplier qualification, manufacturing complexity, or regulatory compliance continues to delay substitution.

What patents protect formulations containing Arachis hypogaea?

Patent protection generally covers the finished formulation rather than the excipient itself. Potential claim categories include:

1. A specific active ingredient dissolved or dispersed in peanut oil.
2. A defined ratio of active ingredient to oil.
3. A softgel composition with a particular shell and fill formulation.
4. A depot injection using peanut oil as the vehicle.
5. A topical composition with defined penetration or stability properties.
6. A method of treating a disease using a product containing the oil.
7. A manufacturing process that controls oxidation, particle size, viscosity, or encapsulation.

The patent strength of these claims depends on whether the oil is essential to the claimed performance. A claim that lists peanut oil among many interchangeable oils may be easier to design around than a claim tied to a demonstrated stability or bioavailability advantage.

How strong is the patent estate for Arachis hypogaea?

The standalone patent estate is weak because the material is an established natural excipient. The strongest potential rights are formulation-specific and may be narrow.

Patent category	Expected strength
Peanut oil as a general excipient	Low
Purification or allergen-reduction process	Moderate if technically distinctive
Specific drug-in-oil formulation	Moderate to strong, depending on data
Softgel or depot delivery system	Moderate
Method of use	Product-specific and dependent on claim scope
Supplier-specific manufacturing process	Strong only against direct process copying

Patent searches should focus on the active drug, dosage form, assignee, and formulation language. Searching only for “Arachis hypogaea” will understate relevant patent exposure because claims may use “peanut oil,” “arachis oil,” “vegetable oil,” or broader lipid terminology.

What formulation and manufacturing barriers affect the market?

The main barriers are quality and risk management, not basic chemical availability.

Allergen control

Peanut allergy is the primary commercial constraint. Pharmaceutical labeling requirements differ by jurisdiction, but regulators and product sponsors generally treat peanut-derived ingredients as material safety information. The European Medicines Agency requires excipient information for medicinal products and identifies peanut oil as an excipient requiring prominent product information because of allergy concerns (European Medicines Agency, 2017).

Refining can reduce protein content, but suppliers must validate controls rather than rely on the assumption that refined oil is allergen-free. Cross-contact prevention, validated testing, supplier audits, and batch traceability increase cost.

Oxidation and shelf life

Peanut oil is susceptible to oxidation. Peroxide value, anisidine value, antioxidant use, nitrogen flushing, light protection, and container selection affect shelf life. Oxidative degradation can reduce product stability and create impurities that complicate regulatory filings.

Agricultural supply

Input costs depend on peanut acreage, weather, disease, crop quality, crushing capacity, and food-market demand. A pharmaceutical supplier may face a tighter market than a commodity buyer because it needs consistent quality, documented provenance, and validated change control.

Supplier qualification

Drug manufacturers typically qualify suppliers through audits, technical agreements, change-notification obligations, and stability data. Once an oil is embedded in an approved formulation, changing suppliers can require comparability work even where the compendial name is unchanged.

How does Arachis hypogaea compare with competing pharmaceutical oils?

Excipient	Main advantages	Main disadvantages
Arachis hypogaea oil	Established solvent and vehicle; suitable for lipophilic drugs	Peanut-allergy risk; agricultural variability
Soybean oil	Broad availability; extensive pharmaceutical history	Allergen and oxidation considerations; possible supply volatility
Sesame oil	Established injectable and depot-use history	Allergen concerns; distinct sensory and physicochemical profile
Sunflower oil	Broad acceptance and relatively favorable consumer perception	May require formulation-specific stability work
MCT oil	Oxidative stability and consistent composition	Different solubility and pharmacokinetic behavior
Mineral oil	Chemical stability; low oxidation	Limited suitability for some drug-delivery applications
Synthetic lipids	High compositional control	Higher cost and possible regulatory development burden

The closest substitutes depend on the dosage form. MCT oil and synthetic lipids are stronger alternatives in modern lipid delivery systems. Sesame and soybean oils may be more relevant for established oil-based dosage forms. Substitution is not automatic because oil polarity, viscosity, fatty-acid composition, and drug solubility can alter bioavailability and stability.

What are the market dynamics for Arachis hypogaea excipient suppliers?

Demand is stable but specialized. Growth is tied to several narrow markets:

• Existing oil-based oral medicines.
• Depot and long-acting formulations.
• Dermatological products.
• Nutraceutical and medical-food crossover demand.
• Contract development and manufacturing services.
• Reformulation work involving lipid solubilization.

The market has low differentiation at the commodity level. Pharmaceutical-grade supply creates a premium through testing, documentation, validated refining, packaging, and regulatory support.

Supplier bargaining power increases when a drug manufacturer has only one qualified source. Buyer bargaining power increases when the formulation can switch to soybean, sunflower, MCT, or synthetic lipid without changing clinical performance.

What is the financial trajectory for Arachis hypogaea pharmaceutical excipients?

No major public company normally reports Arachis hypogaea pharmaceutical excipient revenue as a separate line item. The financial trajectory is therefore a margin and demand analysis rather than a reported revenue forecast.

Base case

Revenue remains stable to modestly growing, supported by legacy products and recurring demand for qualified pharmaceutical-grade oil. Pricing is likely to track agricultural input costs and quality-control requirements.

Upside case

Growth improves if lipid-based drug delivery, long-acting injectables, and softgel products expand and if suppliers offer validated low-protein, low-peroxide, or highly traceable grades. Contract manufacturers may capture more value than raw-material producers because formulation and regulatory support carry higher margins.

Downside case

Demand declines where sponsors reformulate to avoid peanut-derived ingredients, adopt synthetic lipids, or consolidate products into allergen-free platforms. A major allergen-related regulatory event or supply interruption could accelerate substitution.

The most attractive financial positions are likely to sit in:

1. Validated pharmaceutical-grade supply.
2. Low-residual-protein and allergen-control technology.
3. Oxidation-control systems.
4. Dual-source qualification support.
5. Formulation development using lipid excipients.

Commodity peanut-oil production has lower defensibility and greater exposure to agricultural pricing.

Which companies are challenging Arachis hypogaea-based products?

There is no Paragraph IV challenger or biosimilar challenger directed at Arachis hypogaea oil itself. Competition occurs through:

• Generic versions of finished drugs containing peanut oil.
• Reformulated products using alternative oils.
• New lipid-based delivery systems.
• Suppliers of competing pharmaceutical oils.
• Contract manufacturers with proprietary softgel or depot technologies.

A generic manufacturer can challenge a finished product while retaining peanut oil, replacing it with another excipient where regulatory requirements permit, or pursuing a formulation that avoids the relevant patent claims.

What litigation and licensing issues affect the excipient?

Arachis hypogaea oil is unlikely to generate standalone patent litigation because the ingredient is established and broadly available. Disputes are more likely to concern:

• Finished-drug formulation patents.
• Supplier qualification and change-control obligations.
• Quality failures or contamination.
• Confidential manufacturing processes.
• Technology licenses for softgel, depot, or lipid-delivery platforms.
• Trade secrets involving purification or oxidation control.

Licensing economics are usually attached to a drug-delivery technology or finished product, not to the right to use peanut oil as an excipient.

What generic entry risks exist for drugs containing peanut oil?

Generic entry risk is product-specific. The main questions are:

• Whether the reference product’s formulation is patent-protected.
• Whether the oil is necessary for bioequivalence.
• Whether the generic must match the inactive ingredient or only demonstrate equivalent performance.
• Whether the formulation carries allergen-related labeling obligations.
• Whether the product has limited supplier availability.
• Whether a substitute oil changes absorption, stability, or tolerability.

A peanut-oil formulation can create a commercial barrier without creating a strong patent barrier. Regulatory complexity, patient acceptance, and supplier qualification may slow entry, but they do not replace enforceable patent rights.

What is the geographic coverage of Arachis hypogaea excipient regulation?

The United States relies on FDA inactive-ingredient precedent, product-specific labeling, and applicable USP-NF standards. The European Union applies excipient disclosure requirements under product information rules and European Pharmacopoeia quality expectations. Other markets may impose different allergen statements, pharmacopoeial requirements, and import controls.

Global suppliers must manage:

• Country-specific allergen labeling.
• Pharmacopoeial equivalence.
• Food and pharmaceutical supply-chain segregation.
• Import documentation.
• Genetically modified material policies where applicable.
• Regional limits on residual proteins and contaminants.

Key Takeaways

• Arachis hypogaea is peanut oil used as a pharmaceutical solvent, vehicle, emollient, and lipid carrier.
• It has no standalone Orange Book listing, patent term, FDA exclusivity, or Paragraph IV pathway.
• Its strongest commercial uses are in established oil-based oral, topical, and selected parenteral formulations.
• Peanut-allergy risk is the main regulatory and commercial constraint.
• Pharmaceutical-grade value comes from refining, allergen control, oxidation control, documentation, and supplier qualification.
• Revenue is not separately disclosed by most suppliers, so the financial outlook must be inferred from broader excipient and lipid-delivery markets.
• The base case is stable to modest growth, with downside risk from reformulation toward MCT, sunflower, soybean, or synthetic lipids.
• Formulation patents may protect finished drugs containing peanut oil, but they do not create general exclusivity over the excipient.
• The most defensible supplier positions are in validated, traceable, low-protein, low-peroxide pharmaceutical grades.

FAQs

Is Arachis hypogaea oil the same as peanut oil?

Yes. Arachis hypogaea is the botanical species from which peanut oil is derived. Pharmaceutical documents may use “arachis oil,” “peanut oil,” or “Arachis hypogaea oil.”

Can peanut oil be used in injectable medicines?

It can be used in selected oil-based injectable formulations, subject to route-specific safety, sterility, endotoxin, oxidation, and allergen controls. Acceptability depends on the product and jurisdiction.

Does refined peanut oil eliminate peanut-allergy risk?

Refining can reduce protein content, but sponsors must rely on validated manufacturing controls and applicable regulatory requirements. Refinement alone does not eliminate the need for product-specific risk assessment.

Is Arachis hypogaea oil protected by pharmaceutical patents?

The general excipient is not meaningfully protected by a standalone patent estate. Patents may cover a particular drug formulation, dosage form, manufacturing process, or therapeutic use that includes peanut oil.

Which excipients are the best substitutes for Arachis hypogaea oil?

Potential substitutes include soybean oil, sesame oil, sunflower oil, MCT oil, mineral oil, and synthetic lipids. The appropriate substitute depends on drug solubility, route, stability, release profile, and regulatory history.

References

1. DailyMed. (n.d.). Prometrium: Progesterone capsule, gelatin coated prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. European Medicines Agency. (2017). Excipients in the labelling and package leaflet of medicinal products for human use. https://www.ema.europa.eu/

3. U.S. Food and Drug Administration. (n.d.-a). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.